Combining haplo-identical and cord blood stem cell grafts – might the whole be greater than the sum of its parts?

References

• Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–1040.
   PubMed Web of Science ®Google Scholar
• Gu Z, Wang L, Yuan L, et al. Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget. 2017;8(38):63574–63586.
   PubMedGoogle Scholar
• Santoro N, Labopin M, Giannotti F, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11(1):55.
   PubMed Web of Science ®Google Scholar
• Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375(10):944–953.
   PubMed Web of Science ®Google Scholar
• Shouval R, Fein JA, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6(11):e573–e84.
   PubMed Web of Science ®Google Scholar
• Yun HD, Varma A, Hussain MJ, et al. Clinical relevance of immunobiology in umbilical cord blood transplantation. J Clin Med. 2019;8:E1968.
   PubMed Web of Science ®Google Scholar
• Van Besien K, Liu H, Jain N, et al. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013;19(5):682–691.
   PubMed Web of Science ®Google Scholar
• Rocha V, Spellman S, Zhang MJ, et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2012;18(12):1890–1896.
   PubMed Web of Science ®Google Scholar
• van Rood JJ, Scaradavou A, Stevens CE. Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Natl Acad Sci USA. 2012;109(7):2509–2514.
   PubMed Web of Science ®Google Scholar
• Kanaan SB, Gammill HS, Harrington WE, et al. Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant. Oncoimmunology. 2017;6(5):e1311436.
   PubMed Web of Science ®Google Scholar
• Opstelten R, Slot MC, Lardy NM, et al. Determining the extent of maternal-foetal chimerism in cord blood. Sci Rep. 2019;9(1):5247.
   PubMedGoogle Scholar
• Hiwarkar P, Qasim W, Ricciardelli I, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015;126(26):2882–2891.
   PubMed Web of Science ®Google Scholar
• Luevano M, Daryouzeh M, Alnabhan R, et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73(3):248–257.
   PubMed Web of Science ®Google Scholar
• Gergis U, Frenet EM, Shore T, et al. Adoptive immunotherapy with cord blood for the treatment of refractory acute myelogenous leukemia: feasibility, safety, and preliminary outcomes. Biol Blood Marrow Transplant. 2019;25(3):466–473.
   PubMed Web of Science ®Google Scholar
• Li X, Dong Y, Li Y, et al. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study. BMC Cancer. 2019;19(1):819.
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Champlin RE, et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019;3(12):1858–1867.
   PubMed Web of Science ®Google Scholar
• Tsai SB, Rhodes J, Liu H, et al. Reduced-intensity allogeneic transplant for acute myeloid leukemia and myelodysplastic syndrome using combined CD34-selected haploidentical graft and a single umbilical cord unit compared with matched unrelated donor stem cells in older adults. Biol Blood Marrow Transplant. 2018;24(5):997–1004.
   PubMed Web of Science ®Google Scholar
• Lyu H, Lu W, Yao J, et al. Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation. Leuk Lymphoma. 2020;61(4):840–847.
   PubMedGoogle Scholar
• Chen J, Wang RX, Chen F, et al. Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplant. 2014;49(2):206–211.
   PubMed Web of Science ®Google Scholar
• Ke P, Bao XB, Hu XH, et al. Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients. Bone Marrow Transplant. 2018;53(2):162–168.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Z, Wei W, et al. Cord haploidentical non-in vitro T cell depletion allogeneic hematopoietic stem cell transplantation reduces relapse of refractory acute leukemia. Biol Blood Marrow Transplant. 2019;25(1):121–128.
   PubMed Web of Science ®Google Scholar
• Yang J, Jiang J, Cai Y, et al. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transplant. 2019;54:1049–1057.
   PubMed Web of Science ®Google Scholar